Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies

The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics

(2022) Eric Karran et al.   NATURE REVIEWS DRUG DISCOVERY

Faulty autolysosome acidification in Alzheimer’s disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques

(2022) Ju-Hyun Lee et al.   NATURE NEUROSCIENCE

Exogenous Aβ1-42 monomers improve synaptic and cognitive function in Alzheimer's disease model mice

(2022) Yanhong Duan et al.   NEUROPHARMACOLOGY

Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer’s Disease

(2022) Deli Wang et al.   Therapeutic Innovation & Regulatory Science

Proteins Do Not Replicate, They Precipitate: Phase Transition and Loss of Function Toxicity in Amyloid Pathologies

(2022) Kariem Ezzat et al.   Biology-Basel

High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer’s Disease-Causing Mutations

(2022) Andrea Sturchio et al.   JOURNAL OF ALZHEIMERS DISEASE

Synaptogenic effect of APP -Swedish mutation in familial Alzheimer’s disease

(2022) Bo Zhou et al.   Science Translational Medicine

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes

(2022) Sergey Shcherbinin et al.   JAMA Neurology

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease

(2022) Michael J. Pontecorvo et al.   JAMA Neurology

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease

(2022) Susanne Ostrowitzki et al.   JAMA Neurology

Lecanemab for Alzheimer's disease: tempering hype and hope

(2022) The Lancet   LANCET

Alzheimer's disease

(2021) Philip Scheltens et al.   LANCET

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

(2021) Chad J. Swanson et al.   Alzheimers Research & Therapy

Soluble Amyloid-β Consumption in Alzheimer’s Disease

(2021) Alberto J. Espay et al.   JOURNAL OF ALZHEIMERS DISEASE

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

(2021) Stephen Salloway et al.   NATURE MEDICINE

Can we learn lessons from the FDA’s approval of aducanumab?

(2021) Kathy Y. Liu et al.   Nature Reviews Neurology

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques

(2021) Yan Li et al.   NEUROLOGY

FDA Drug Approval and the Ethics of Desperation

(2021) Emily A. Largent et al.   JAMA Internal Medicine

The β-secretase BACE1 in Alzheimer’s disease

(2020) Harald Hampel et al.   BIOLOGICAL PSYCHIATRY

The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeutics

(2020) Sarah A. Kent et al.   ACTA NEUROPATHOLOGICA

The Use of Antimicrobial and Antiviral Drugs in Alzheimer’s Disease

(2020) Umar H. Iqbal et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain

(2020) Cyrille Sur et al.   BRAIN

Amyloid-β Immunotherapy for Alzheimer's Disease - Is It Now A Long Shot…?

(2019) Francesco Panza et al.   ANNALS OF NEUROLOGY

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

(2019) Francesco Panza et al.   Nature Reviews Neurology

Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

(2019) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

(2019) Michael F. Egan et al.   Alzheimers Research & Therapy

Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients?

(2019) Francesco Panza et al.   AGEING RESEARCH REVIEWS

Investigational BACE inhibitors for the treatment of Alzheimer’s disease

(2019) Bruno P. Imbimbo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics

(2018) Brendan P. Lucey et al.   ANNALS OF NEUROLOGY

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

(2018) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

(2018) Lawrence S. Honig et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease

(2018) Holly M. Brothers et al.   Frontiers in Aging Neuroscience

Plasma Aβ42 as Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study

(2018) Diego Albani et al.   JOURNAL OF ALZHEIMERS DISEASE

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons

(2017) Michael C. Donohue et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Amyloid-β Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory

(2017) Agostino Palmeri et al.   JOURNAL OF NEUROSCIENCE

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

(2017) Susanne Ostrowitzki et al.   Alzheimers Research & Therapy

Reexamining Alzheimer's Disease: Evidence for a Protective Role for Amyloid-β Protein Precursor and Amyloid-β

(2017) Rudy J. Castellani et al.   JOURNAL OF ALZHEIMERS DISEASE

A Physiological Role for Amyloid-β Protein: Enhancement of Learning and Memory

(2017) John E. Morley et al.   JOURNAL OF ALZHEIMERS DISEASE

Is Brain Amyloid Production a Cause or a Result of Dementia of The Alzheimer's Type?

(2017) Robert G. Struble et al.   JOURNAL OF ALZHEIMERS DISEASE

Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer’s Disease

(2016) Paul B. Rosenberg et al.   JOURNAL OF ALZHEIMERS DISEASE

Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study

(2016) Samantha C Burnham et al.   LANCET NEUROLOGY

Effects of Heart Bypass Surgery on Plasma Aβ40 and Aβ42 Levels in Infants and Young Children

(2016) Yaoqin Hu et al.   MEDICINE

Alzheimer’s disease due to loss of function: A new synthesis of the available data

(2016) Kasper P. Kepp   PROGRESS IN NEUROBIOLOGY

Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community

(2016) Ronald C. Petersen et al.   JAMA Neurology

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

(2015) Willemijn J. Jansen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The keystone of Alzheimer pathogenesis might be sought in Aβ physiology

(2015) D. Puzzo et al.   NEUROSCIENCE

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease

(2015) Rachelle S Doody et al.   Alzheimers Research & Therapy

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Beneficial effect of amyloid beta after controlled cortical impact

(2013) Rebekah C. Mannix et al.   BRAIN INJURY

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study

(2013) Stephanie JB Vos et al.   LANCET NEUROLOGY

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease

(2013) Gaël Chételat et al.   NeuroImage-Clinical

Open-heart surgery increases cerebrospinal fluid levels of Alzheimer-associated amyloid β

(2012) B. REINSFELT et al.   ACTA ANAESTHESIOLOGICA SCANDINAVICA

Rational heterodoxy: Cholesterol reformation of the amyloid doctrine

(2012) Michael A. Castello et al.   AGEING RESEARCH REVIEWS

Amyloid-β Immunotherapy for Alzheimers Disease

(2012) H.J. Fu et al.   CNS & Neurological Disorders-Drug Targets

Deciphering the mechanism underlying late-onset Alzheimer disease

(2012) Dimitrije Krstic et al.   Nature Reviews Neurology

Is Alzheimer’s disease amyloidosis the result of a repair mechanism gone astray?

(2011) Tyler A. Kokjohn et al.   Alzheimers & Dementia

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

(2011) Victor L. Villemagne et al.   ANNALS OF NEUROLOGY

Reimagining Alzheimer's Disease--An Age-Based Hypothesis

(2010) K. Herrup   JOURNAL OF NEUROSCIENCE

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

(2010) Christopher C. Rowe et al.   NEUROBIOLOGY OF AGING

Decreased cerebrospinal fluid Aβ42correlates with brain atrophy in cognitively normal elderly

(2009) Anne M. Fagan et al.   ANNALS OF NEUROLOGY

A γ-secretase inhibitor decreases amyloid-β production in the central nervous system

(2009) Randall J. Bateman et al.   ANNALS OF NEUROLOGY

 -Amyloid Monomers Are Neuroprotective

(2009) M. L. Giuffrida et al.   JOURNAL OF NEUROSCIENCE